These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 22369900)

  • 1. Histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits anti-inflammatory activities through induction of mitochondrial damage and apoptosis in activated lymphocytes.
    Shi ZJ; Ouyang DY; Zhu JS; Xu LH; He XH
    Int Immunopharmacol; 2012 Apr; 12(4):580-7. PubMed ID: 22369900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valproic acid exhibits biphasic effects on apoptotic cell death of activated lymphocytes through differential modulation of multiple signaling pathways.
    Chen Q; Ouyang DY; Geng M; Xu LH; Zhang YT; Wang FP; He XH
    J Immunotoxicol; 2011; 8(3):210-8. PubMed ID: 21457087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines.
    Leoni F; Zaliani A; Bertolini G; Porro G; Pagani P; Pozzi P; Donà G; Fossati G; Sozzani S; Azam T; Bufler P; Fantuzzi G; Goncharov I; Kim SH; Pomerantz BJ; Reznikov LL; Siegmund B; Dinarello CA; Mascagni P
    Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2995-3000. PubMed ID: 11867742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
    Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
    Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
    Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).
    Almenara J; Rosato R; Grant S
    Leukemia; 2002 Jul; 16(7):1331-43. PubMed ID: 12094258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib.
    Emanuele S; Lauricella M; Carlisi D; Vassallo B; D'Anneo A; Di Fazio P; Vento R; Tesoriere G
    Apoptosis; 2007 Jul; 12(7):1327-38. PubMed ID: 17351739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines.
    Lillehammer T; Engesaeter BO; Prasmickaite L; Maelandsmo GM; Fodstad O; Engebraaten O
    J Gene Med; 2007 Jun; 9(6):440-51. PubMed ID: 17410615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
    You BR; Han BR; Park WH
    Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid.
    Rikiishi H; Shinohara F; Sato T; Sato Y; Suzuki M; Echigo S
    Int J Oncol; 2007 May; 30(5):1181-8. PubMed ID: 17390020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined effects of sulindac and suberoylanilide hydroxamic acid on apoptosis induction in human lung cancer cells.
    Seo SK; Jin HO; Lee HC; Woo SH; Kim ES; Yoo DH; Lee SJ; An S; Rhee CH; Hong SI; Choe TB; Park IC
    Mol Pharmacol; 2008 Mar; 73(3):1005-12. PubMed ID: 18156316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
    Butler LM; Agus DB; Scher HI; Higgins B; Rose A; Cordon-Cardo C; Thaler HT; Rifkind RA; Marks PA; Richon VM
    Cancer Res; 2000 Sep; 60(18):5165-70. PubMed ID: 11016644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced suppression of tumor growth by concomitant treatment of human lung cancer cells with suberoylanilide hydroxamic acid and arsenic trioxide.
    Chien CW; Yao JH; Chang SY; Lee PC; Lee TC
    Toxicol Appl Pharmacol; 2011 Nov; 257(1):59-66. PubMed ID: 21889949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitors induce mitochondrial elongation.
    Lee JS; Yoon YG; Yoo SH; Jeong NY; Jeong SH; Lee SY; Jung DI; Jeong SY; Yoo YH
    J Cell Physiol; 2012 Jul; 227(7):2856-69. PubMed ID: 21928346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer activity of SAHA, a potent histone deacetylase inhibitor, in NCI-H460 human large-cell lung carcinoma cells in vitro and in vivo.
    Zhao Y; Yu D; Wu H; Liu H; Zhou H; Gu R; Zhang R; Zhang S; Wu G
    Int J Oncol; 2014 Feb; 44(2):451-8. PubMed ID: 24297449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SAHA, an HDAC inhibitor, attenuates antibody-mediated allograft rejection.
    Zhang X; Guo M; Kang Y; Liu F; Zheng X; Han S; Fu S; Hong S; Ding G; Wang L; Wang QX
    Transplantation; 2013 Sep; 96(6):529-37. PubMed ID: 23912176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of apoptosis in renal tubular cells by histone deacetylase inhibitors, a family of anticancer agents.
    Dong G; Wang L; Wang CY; Yang T; Kumar MV; Dong Z
    J Pharmacol Exp Ther; 2008 Jun; 325(3):978-84. PubMed ID: 18310471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anti-inflammatory effect of the SOCC blocker SK&F 96365 on mouse lymphocytes after stimulation by Con A or PMA/ionomycin.
    Ye Y; Zhang Y; Lu X; Huang X; Zeng X; Lai X; Zeng Y
    Immunobiology; 2011 Sep; 216(9):1044-53. PubMed ID: 21470712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1.
    Leng C; Gries M; Ziegler J; Lokshin A; Mascagni P; Lentzsch S; Mapara MY
    Exp Hematol; 2006 Jun; 34(6):776-87. PubMed ID: 16728283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.